En Es
Categories

Industry News

Companies with Lab-Developed Tests Raise USD 2 Billion

By Labmedica International staff writers
11 Oct 2017

Image: Companies with laboratory-developed tests are attracting increasing investor interest and raised over USD 2 billion between January and August 2017 (Photo courtesy of iStock).Companies with laboratory-developed tests (LTDs), tests performed by laboratories owned by IVD companies and others, are attracting increasing investor interest and raised over USD 2 billion between January and August 2017. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

LDTs, also called as "home-brew tests" or "in-house tests" were historically low-volume, simple and well-characterized tests for low-risk diagnostic applications. However, in recent years, there has been increased focus and attention on the emergence and growing use of complex LDTs based on technologies such as polymerase chain reaction (PCR), microarrays, next generation sequencing, or other complex technology. High-risk, complex tests have now been developed as LDTs in order to provide clinical results to physicians and their patients.

Presently, LDTs are being used for complex testing which smaller laboratories are not equipped or do not choose to handle and are used for a variety of medical conditions. There are all types of LDTs, including histology and molecular testing to immunoassays; or equipment-intensive testing such as mass spectrometry or flow cytometry. The largest segments of the LDTs market are oncology, genetic (inherited) disorders, and infectious disease, although these tests can be developed and used for virtually all types of disorders.

The significant activity in the development of new LDTs, increasing revenues from current LDTs, and the large addressable markets for several emerging LDTs has attracted the interest of investors as well as of other companies looking for acquisitions. For instance, in 2016, the companies included in Kalorama’s report raised over USD 750 million, although this amount was much smaller in comparison to the over USD 2 billion raised between January and August 2017.

The LDTs market has also witnessed a significant number of acquisitions in recent years, with the major companies making several acquisitions to achieve their current market positions, while smaller clinical laboratories have also been making acquisitions. A number of new companies also continue to be founded, thus providing a continuous stream of smaller companies trying to achieve growth, which may come through acquisitions or they may end up being acquired. Hence, consolidation among companies and laboratories offering LDTs is expected to continue in the future.

Related Links:
Kalorama Information



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More
08 Feb 2018
AI Could Learn How to Understand Radiologist Reports
Researchers at the Icahn School of Medicine at Mount Sinai have used machine learning techniques, including natural language processing algorithms, to identify clinical concepts in radiologist reports for computed tomography (CT) scans. The technology marks an important first step in the development of artificial intelligence (AI) that could interpret scans and diagnose conditions.
Read More
08 Feb 2018
AR and VR in Healthcare Market to Reach USD 4.9 Million by 2023
The augmented reality (AR) and virtual reality (VR) in the healthcare market was valued at USD 769.2 million in 2017 and is expected to grow at a CAGR of 36.6% during the forecast period to reach USD 4,997.9 million by 2023. The market growth will be driven by increasing penetration of connected devices in the healthcare sector, rising investment in healthcare AR and VR, and growing need to reduce healthcare costs. However, the lack of competence in the deployment of AR and VR solutions, and lack of expertise among medical practitioners to adopt new technologies are the major restraints for market growth.
Read More
08 Feb 2018
Elekta Collaborates with IBM Watson Health to Bring AI to Oncology
Elekta is collaborating with IBM Watson Health to offer Watson for Oncology with its cancer care solutions. Beginning in early 2018, Elekta will sell Watson for Oncology as a clinical decision support solution, paired within its digital cancer care solutions, including the MOSAIQ Oncology Information System.
Read More
08 Feb 2018
AR System Allows Surgeons to Reconnect Blood Vessels
A team of researchers at Imperial College London at St Mary’s Hospital has demonstrated the use of Microsoft HoloLens headset for performing reconstructive lower limb surgery on patients. The HoloLens is a self-contained computer headset that immerses the wearer in ‘mixed reality’, allowing them to interact with ‘holograms’ which are computer-generated objects made visible through the visor.
Read More
29 Jan 2018
Top Drivers of Global Laboratory Centrifuge Market
The global laboratory centrifuge market is expected to grow steadily at a CAGR of more than 5% during the forecast period 2017-2022, driven mainly by the increasing number of biotechnology and pharmaceutical research studies, growing use of molecular diagnostics in hospitals, and technological advancements.
Read More
29 Jan 2018
Patient Positioning Systems Market to Reach USD 1.4 Billion by 2025
The global patient positioning systems market was valued at USD 942.8 million in 2016 and is expected to grow at a CAGR of 4.7% during the 2014 - 2025 forecast period to reach USD 1.4 billion by 2025, driven by a growing geriatric population, rising incidence of cancer, increasing awareness among patients, and surge in expenditure on diagnostic procedures. Additionally, technological advancements in sensors, such as optic fiber technology, cancer tracking sensors, and MEMS sensors, are expected to further boost the market growth.
Read More
18 Jan 2018
Siemens Healthineers Strategy 2025 to Focus on AI
Siemens Healthineers has laid out its strategy to bolster its market leadership by 2025 and beyond, aimed at accelerating profitable growth and delivering return. The company has stated that it is well prepared to take advantage of the paradigm shift and structural growth opportunities in healthcare.
Read More
16 Jan 2018
GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform
GE Healthcare and Roche have entered into a strategic, long-term partnership to jointly develop and co-market digital clinical decision support solutions. Initially, the partnership will focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions